vimarsana.com

Page 70 - குறிப்பு தொடர்பாக முன்னோக்கி பார்க்கிறது அறிக்கைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ImmuCell Closes $4,250,000 Equity Financing

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ImmuCell Closes $4,250,000 Equity Financing ImmuCell CorporationApril 14, 2021 GMT PORTLAND, Maine, April 14, 2021 (GLOBE NEWSWIRE) ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has closed an equity investment. On April 14, 2021, the Company issued the aggregate of 515,156 common shares at $8.25 per share directly to its largest stockholder (the Pessin family) and several other investors, raising gross proceeds of $4,250,037, with minimal closing costs. These shares have been registered under the Company’s effective shelf registration statement on Form S-3.

Heatherdale Resources Ltd : Heatherdale Announces Closing of $5 4 Million Private Placement

Heatherdale Resources Ltd.: Heatherdale Announces Closing of $5.4 Million Private Placement Heatherdale or the Company ) (TSXV:HTR) announces that it has closed its previously announced private placement of common shares (the Offering ). A total of 6,747,500 common shares (the Common Shares ) were sold at price of $0.80 per Common Share, for aggregate gross proceeds of $5,398,000. The proposed name change will follow shortly. The net proceeds of the Offering will be used to fund exploration activities on the Company s Niblack Cu-Au-Zn-Ag project located in Alaska, property acquisitions and working capital purposes. The Company paid aggregate finder s fees of $110,280 and issued 137,850 share purchase warrants (the

Entera Appoints Ramesh Ratan as Chief Financial Officer

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Entera Appoints Ramesh Ratan as Chief Financial Officer Entera Bio Ltd.April 15, 2021 GMT BOSTON and JERUSALEM, Israel, April 15, 2021 (GLOBE NEWSWIRE)  Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of veteran finance and operations executive Ramesh Ratan as U.S. Chief Financial Officer. Mr. Ratan replaces Jonathan Lieber who was serving as Entera’s interim U.S. CFO. Mr. Ratan brings 40 years of experience at biomedical, tech, and Fortune 500 companies in senior, executive, vice president, and C-level positions. He was most recently CFO, Head of Manufacturing, and Corporate Secretary at AOBiome. He served as CFO at Xcellerex, Enanta Pharmaceuticals, Repligen, and held positions at Bristol-Myers Squibb, American Superconductor, and Equinox Solutions. As CFO, he raised over $300 million an

ReconAfrica s First of Three Wells Confirms a Working Petroleum System in the Kavango Basin, Namibia

ReconAfrica s First of Three Wells Confirms a Working Petroleum System in the Kavango Basin, Namibia
newswire.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswire.ca Daily Mail and Mail on Sunday newspapers.

Northern Vertex Reports Fiscal Results for Six Months Ended December 31, 2020

Northern Vertex Reports Fiscal Results for Six Months Ended December 31, 2020 News provided by Share this article Northern Vertex Mining Corp. (TSX: NEE)  ( Northern Vertex or the Company ) a U.S.-focused gold producer with district-scale exploration potential in the Walker Lane Trend, is pleased to announce audited financial results for its new fiscal year end to December 31 st. Results for the fiscal six months ended December 31, 2020 ( Stub Year ) included revenue of $52.7 million, Adjusted EBITDA of $23.3m, and a positive working capital position of $10.9m. All figures are expressed in USD unless otherwise noted, non-IFRS metrics are described later in this press release.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.